Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NPLEx Brings A ‘Quiet’ Year On State PSE Legislation – CHPA

This article was originally published in The Tan Sheet

Executive Summary

CHPA President and CEO Scott Melville says 2015 is the “quietest” in five years for state legislation on the sale of pseudoephedrine, a testament to NPLEx. Bills for Rx-only PSE sales introduced in four states this year failed.

You may also be interested in...



States With Age Restriction On OTC DXM Sales Number 17 – And Counting

Pennsylvania is 17th US state to limit sales of dextromethorphan OTCs to consumers 18 and older because teenagers' abuse of the ingredient for intoxicating effect remains a common problem.

States With Age Restriction On OTC DXM Sales Number 17 – And Counting

Pennsylvania is 17th US state to limit sales of dextromethorphan OTCs to consumers 18 and older because teenagers' abuse of the ingredient for intoxicating effect remains a common problem.

Two States Require Industry To Pay For Ongoing Drug Take-Back Programs

Consumer Healthcare Products Association looks to stem expansion of state-mandated drug take-back programs with programs that use existing facilities and infrastucture and don't require industry funidng, says state affairs VP Carlos Gutierrez. State bills limiting sales of DXM to minors and expansion of the NPLEx system to track PSE sales also are on CHPA’s radar.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS107777

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel